CHAMPIONS ONCOLOGY, INC. generated $15.232 million in Oncology Revenue for the three months ended July 31, compared with $13.995 million a year earlier, while recording a $426 thousand net loss. Cash and expected operating flows were considered adequate to fund operations through at least September 2027.

Key Highlights

  • The operating loss narrowed to $409 thousand from $527 thousand in the comparable period.
  • Oncology revenue increased to $15.232 million from $13.995 million.
  • Cash and cash equivalents totaled $4.358 million at July 31, 2026.

Quarterly Revenue And Earnings

Sales and Marketing expenses rose to $3.090 million from $1.855 million. General and administrative expenses were $2.673 million, compared with $2.570 million. CHAMPIONS ONCOLOGY, INC. (NASDAQ: CSBR) recorded no loss on equipment disposal in the latest period, versus $20 thousand previously. The resulting loss from operations was $409 thousand, compared with $527 thousand.

Oncology Revenue Mix

TOS data-license revenue was $893 thousand, up from $311 thousand. Other TOS revenue was $183 thousand, compared with $454 thousand. The arrangements involve tumor samples used in developing PDX models and in the company’s pharmacology TOS business.

Cash, Assets And Liabilities

Cash and cash equivalents were $4.358 million at July 31, compared with $4.872 million at April 30. Accounts receivable, net, stood at $13.602 million, up from $13.178 million, while prepaid expenses and other current assets were $1.332 million compared with $1.169 million. Total current assets reached $19.292 million, compared with $19.219 million. Deferred revenue increased to $9.552 million from $8.828 million, while total current liabilities fell to $18.729 million from $19.922 million. Non-current operating Lease liabilities were $9.886 million, compared with $2.992 million. Total liabilities stood at $28.830 million, versus $22.921 million.

Operating Cash And Funding Outlook

The company also said it may need to raise additional Capital or obtain financing, with the outcome dependent on whether financing could be secured on acceptable terms.